APR 10, 2019 11:45 AM PDT

Dovato: Approved Drug for HIV-1

WRITTEN BY: Nouran Amin

Roughly 1.1 million people in the U.S. live with HIV with 15 percent of that population unaware they are infected. Treating these individuals must be highly effective to suppress the viral load in the blood that is needed to prevent disease progression. Now, the U.S. Food and Drug Administration has granted approval for the two-drug, fixed-dose, complete regimen for HIV-infected adults—the drug is called Dovato (dolutegravir and lamivudine).

“Currently, the standard of care for patients who have never been treated is a three-drug regimen. With this approval, patients who have never been treated have the option of taking a two-drug regimen in a single tablet while eliminating additional toxicity and potential drug interactions from a third drug,” said Debra Birnkrant, M.D., Director of the Division of Antiviral Products. “Having a drug-sparing treatment available that uses fewer drugs is beneficial to patients who may have issues taking multiple medications over a long period of time.”

Dovato was proven successful in clinical trials when the treatment maintained low-levels (less than 50 copies/mL) of HIV RNA in the blood for at least 48 weeks.

However, Dovato comes with warning to those patients infected with both HIV and hepatitis B—that they must seek additional treatment for their hepatitis B or possibly a different drug regimen. Additionally, those patients with both HIV and hepatitis B who take other treatments containing lamivudine--an ingredient in Dovato--have developed variants of hepatitis B that is associated with resistance to lamivudine and may cause severe liver problems, including liver failure after they stop taking stop taking drugs containing lamivudine. Therefore, patients with HIV and hepatitis B virus, who stop using Dovato, should closely monitor with their physician.

Additionally, patients are strongly recommend to avoid Dovato treatment at the time of conception through the first trimester of pregnancy because there is a known risk for neural tube defects with dolutegravir. Other adverse effects of Dovato include most commonly headache, diarrhea, nausea, insomnia and fatigue.

The approval of Dovato was granted to ViiV Healthcare.

Source: FDA

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
AUG 10, 2021
Drug Discovery & Development
Epidemiology and postexposure prophylaxis of rabies virus
AUG 10, 2021
Epidemiology and postexposure prophylaxis of rabies virus
Rabies is a viral disease that can be transmitted from an infected animal to another animal or human. In the U ...
AUG 12, 2021
Drug Discovery & Development
Postpartum depression drug works through altering brain waves
AUG 12, 2021
Postpartum depression drug works through altering brain waves
     Postpartum depression is a form of depression that occurs after childbirth. This form of depres ...
AUG 21, 2021
Neuroscience
Is Humor the Best Way to Deliver Public Health Interventions?
AUG 21, 2021
Is Humor the Best Way to Deliver Public Health Interventions?
Humor is an effective way to deliver public health interventions and influence people’s behavior around their heal ...
SEP 13, 2021
Cell & Molecular Biology
Could This Drug Delivery Capsule Replace Injections?
SEP 13, 2021
Could This Drug Delivery Capsule Replace Injections?
Antibodies are naturally produced by many organisms, as part of immune defense. They also have potential as a therapeuti ...
OCT 21, 2021
Coronavirus
FDA approves mixing and matching COVID booster shots
OCT 21, 2021
FDA approves mixing and matching COVID booster shots
On Wednesday, the United States Food and Drug Administration (FDA) approved Americans to be given a different ...
OCT 26, 2021
Microbiology
A Strategy to Improve the Efficacy of Antibiotics
OCT 26, 2021
A Strategy to Improve the Efficacy of Antibiotics
For many years, scientists and experts have warned about a building crisis - antibiotics are becoming less reliable, bac ...
Loading Comments...